Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 8:04 p.m. and Nov. 22, 2024, 8:04 p.m. from: Genetic Testing Services.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Tagomics Announces a Multiomic Profiling Co-Marketing Agreement with Agilent

Document Date: Nov. 20, 2024, 9:45 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: To showcase the potential of this combined approach, Tagomics has signed a co-marketing agreement with Agilent Technologies, and launched a technology access program which allows select customers to experience the enhanced capabilities of the combined platform ahead of the broader market. Customers will benefit from more comprehensive insights into the mechanisms driving disease, opening the door to novel diagnostic and therapeutic strategies. Dr Jack Kennefick, CEO and co-founder of Tagomics said: "We 're pleased to be working with Agilent Technologies to bring select customers the combined capabilities of our respective platforms, unified in Tagomics' Interlace multiomic workflow. Through this collaboration, we look forward to empowering customers with deeper biological insights and accelerating the development of innovative diagnostic and therapeutic solutions ." Ronda Allen, general manager of Genomics at Agilent Technologies commented: "Through our agreement, our customers will have access to Tagomics' Interlace platform and advanced bioinformatics software, enabling simultaneous genetic and genome-wide epigenomic profiling.
Document Source: https://www.businesswire.com/news/home/20241120251260/en/Tagomics-Announces-a-Multiomic-Profiling-Co-Marketing-Agreement-with-Agilent (archive.org page / archive.org listing)


Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Document Date: Nov. 20, 2024, 9:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) - Myriad Genetics, Inc. (NASDAQ: MYGN) , a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN) , a global leader in DNA sequencing and array - based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2) . Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. " We are pleased to expand our collaboration with Illumina and combine the two companies' technologies to create what we believe is the most advanced and complete gene panel to enable comprehensive genomic profiling ," said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984793/15459/en/Myriad-Genetics-Announces-Incorporation-of-its-Proprietary-HRD-platform-in-Illumina-s-Updated-Comprehensive-Gene-Panel-Assay-TruSight-Oncology-500-v2.html (archive.org page / archive.org listing)


HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Document Date: Nov. 22, 2024, 4:30 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity / Region: Japan
Partnership: Document Extract: On the launch of FRUZAQLA® in Japan by Takeda, Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "The launch of FRUZAQLA® in Japan highlights the continued progress of our partnership with Takeda across the globe. Takeda is well positioned to build on more than a decade of leadership in the treatment of metastatic CRC in Japan and bring a differentiated treatment option in FRUZAQLA® to patients ." The launch of FRUZAQLA® in Japan follows its approval in September 2024, primarily based on results from the Phase III FRESCO-2 trial conducted in the US, Europe, Japan and Australia. Data from FRESCO-2 were published in The Lancet in June 2023. Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau, and markets under the FRUZAQLA® brand name.
Document Source: https://www.globenewswire.com/news-release/2024/11/22/2985718/0/en/HUTCHMED-Announces-Launch-by-Takeda-of-FRUZAQLA-fruquintinib-in-Japan.html (archive.org page / archive.org listing)


23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation

Document Date: Nov. 20, 2024, 12:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Mirador will use the 23andMe database to augment its proprietary Mirador360™ development engine, which already houses one of the most extensive repositories of immune-mediated disease data, including over two million human molecular profiles. " Our new partnership with 23andMe supercharges the Mirador mission to rapidly advance transformational precision therapies for patients living with chronic immune-mediated inflammatory and fibrotic diseases ," said Mark C. McKenna, Chairman and CEO of Mirador. " Combining Mirador360's cutting-edge biology, multi-modal data and AI capabilities with the unparalleled genetic and phenotypic insights from the 23andMe database will enable us to accelerate our progress toward solving major unmet needs in I & I ." " Mirador is a pioneer in I & I precision medicine, and our collaboration harnesses the power of 23andMe's data and research platform to identify new targets and develop promising new drugs ," said Anne Wojcicki, CEO and Co-Founder of 23andMe. " We hope this can ultimately help the millions of patients living with a range of I & I diseases who urgently need treatment options ."
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984324/0/en/23andMe-and-Mirador-Therapeutics-Enter-Into-Strategic-Research-Collaboration-to-Advance-Mirador-s-Precision-Medicines-for-Immunology-Inflammation.html (archive.org page / archive.org listing)


23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation

Document Date: Nov. 20, 2024, 12:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) - 23andMe Holding Co. (Nasdaq: ME) , a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I & I) -related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine. The 23andMe genetic and phenotypic health information database is the world's largest crowdsourced platform for genetic research. Insights gleaned from the 23andMe database have resulted in previous pharma collaborations that have generated multiple drug discovery programs, as well as two clinical stage assets in immuno-oncology, and more than 300 scientific publications. Mirador will use the 23andMe database to augment its proprietary Mirador360™ development engine, which already houses one of the most extensive repositories of immune-mediated disease data, including over two million human molecular profiles.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984324/0/en/23andMe-and-Mirador-Therapeutics-Enter-Into-Strategic-Research-Collaboration-to-Advance-Mirador-s-Precision-Medicines-for-Immunology-Inflammation.html (archive.org page / archive.org listing)


Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

Document Date: Nov. 18, 2024, 6:30 a.m. / Source: Business Wire
Activity Class: PartnershipActivity / Region: Republic of Panama
Partnership: Document Extract: Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives. The first step of the plan focuses on certification and importation of Ikonisys Group's products into Panama, leveraging the region's logistical and operational advantages. Panama's strategic position as a logistics hub will enable streamlined distribution and access to Ikonisys Group's products across Central America (including Costa Rica, Nicaragua, Honduras, Salvador, Guatemala and Belize).
Document Source: https://www.businesswire.com/news/home/20241117538354/en/Ikonisys-Group-enters-Central-America-Market-through-a-Partnership-and-Distribution-Agreement-with-Green-Med-Panama (archive.org page / archive.org listing)


Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

Document Date: Nov. 18, 2024, 6:30 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama. Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives. The first step of the plan focuses on certification and importation of Ikonisys Group's products into Panama, leveraging the region's logistical and operational advantages.
Document Source: https://www.businesswire.com/news/home/20241117538354/en/Ikonisys-Group-enters-Central-America-Market-through-a-Partnership-and-Distribution-Agreement-with-Green-Med-Panama (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.